Goldline IPO Subscribed 21.81x; Retail Leads

Goldline Pharmaceutical Limited's ₹8.35 crore SME initial public offering (IPO) has concluded with a total subscription of 21.81 times. The issue, which opened on May 12, 2026, and closed on May 14, 2026, saw strong interest primarily from retail investors. The company markets pharmaceutical products under its proprietary 'Goldline' brand across five distinct segments, operating entirely on an asset-light, third-party contract manufacturing model with 15 contract manufacturers and 8 distributors.

Subscription Status

The IPO attracted robust demand across investor categories, with the retail segment driving the overall subscription numbers. The Qualified Institutional Buyers (QIB) category recorded a subscription of 1.31 times, while the Non-Institutional Investors (NII) category was divided into sHNI and bHNI segments.

Category Subscription Status Qualified Institutional Buyers (QIB) 1.31 x Non-Institutional Buyers (sHNI) 27.7 x Non-Institutional Buyers (bHNI) 22.06 x Retail 33.18 x Employees 0 x Total Subscribed 21.81 x

IPO Structure and Key Dates

The offering was a pure fresh issue with no Offer for Sale (OFS) component. The net proceeds from the issue are intended for repayment of outstanding borrowings — including unsecured loans, term loans, and working capital facilities — with a portion allocated to general corporate purposes capped at the lower of 15% of gross proceeds or ₹1,000.00 lakhs.

Parameter Details Issue Type Fresh Issue Fresh Issue Size ₹8.35 Crore Offer for Sale (OFS) Nil Total Issue Size ₹8.35 Crore IPO Opening Date 12-May-2026 IPO Closing Date 14-May-2026 Allotment Date 15-May-2026 Listing Date 19-May-2026

Financial Performance

The company has reported consistent revenue growth over the reviewed periods. Revenue from operations grew from ₹19.85 crore in FY2023 to ₹23.57 crore in FY2024 and further to ₹28.06 crore in FY2025. For the nine months ended December 31, 2025 (Q3 FY2026), revenue stood at ₹21.41 crore.

Metric FY2023 FY2024 FY2025 Q3 FY2026 (9M) Revenue from Operations (₹ Cr) 19.85 23.57 28.06 21.41 PAT (₹ Cr) 0.26 1.80 2.83 2.22 PAT Margin (%) 1.31% 7.64% 10.09% 10.37%

Profitability improved significantly over the period, with PAT margin expanding from 1.31% in FY2023 to 10.09% in FY2025. Total equity grew from ₹5.89 crore in FY2023 to ₹12.36 crore as of Q3 FY2026, while the debt-to-equity ratio declined from 2.29x to 1.22x over the same period.

Key Risk Factors

Investors should note material risks including third-party manufacturer dependence, concentrated distribution through only 8 distributors, and related-party revenue dependency where promoter group entities contributed 22.04% of revenue. Geographic concentration is also high, with Maharashtra and Madhya Pradesh accounting for over 70% of revenue. Outstanding litigation includes ₹271.23 lakhs in direct tax matters and ₹63.70 lakhs in indirect tax matters.

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.

We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.

This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.

The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.

We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.

This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.

By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.

We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.